2024
DOI: 10.1056/nejmoa2314585
|View full text |Cite
|
Sign up to set email alerts
|

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Laurent Peyrin-Biroulet,
J. Casey Chapman,
Jean-Frederic Colombel
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
references
References 38 publications
0
0
0
Order By: Relevance